DK2013166T3 - N-carbamoylmethyl-4(R)-phenyl-2-pyrrolidon, fremgangsmåde til fremstilling heraf og farmaceutisk anvendelse - Google Patents

N-carbamoylmethyl-4(R)-phenyl-2-pyrrolidon, fremgangsmåde til fremstilling heraf og farmaceutisk anvendelse

Info

Publication number
DK2013166T3
DK2013166T3 DK07726915.7T DK07726915T DK2013166T3 DK 2013166 T3 DK2013166 T3 DK 2013166T3 DK 07726915 T DK07726915 T DK 07726915T DK 2013166 T3 DK2013166 T3 DK 2013166T3
Authority
DK
Denmark
Prior art keywords
phenyl
carbamoylmethyl
preparation
pyrrolidone
pharmaceutical use
Prior art date
Application number
DK07726915.7T
Other languages
English (en)
Inventor
Grigory Veinberg
Maksim Vorona
Liga Zvejniece
Aleksandrs Chernobrovijs
Ivars Kalvinsh
Ligita Karina
Maija Dambrova
Original Assignee
Akciju Sabiedriba Olainfarm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akciju Sabiedriba Olainfarm filed Critical Akciju Sabiedriba Olainfarm
Application granted granted Critical
Publication of DK2013166T3 publication Critical patent/DK2013166T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
DK07726915.7T 2006-03-16 2007-03-15 N-carbamoylmethyl-4(R)-phenyl-2-pyrrolidon, fremgangsmåde til fremstilling heraf og farmaceutisk anvendelse DK2013166T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LVP-06-45A LV13630B (en) 2006-03-16 2006-03-16 Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone
PCT/EP2007/052424 WO2007104780A2 (en) 2006-03-16 2007-03-15 N- carbamoylmethyl- 4- (r) -phenyl-2-pyrr0lidin0ne, method of its preparation and pharmaceutical use

Publications (1)

Publication Number Publication Date
DK2013166T3 true DK2013166T3 (da) 2010-07-05

Family

ID=38461010

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07726915.7T DK2013166T3 (da) 2006-03-16 2007-03-15 N-carbamoylmethyl-4(R)-phenyl-2-pyrrolidon, fremgangsmåde til fremstilling heraf og farmaceutisk anvendelse

Country Status (21)

Country Link
US (2) US9102615B2 (da)
EP (1) EP2013166B1 (da)
CN (1) CN101448786A (da)
AT (1) ATE460396T1 (da)
CA (1) CA2647206C (da)
CY (1) CY1110170T1 (da)
DE (1) DE602007005244D1 (da)
DK (1) DK2013166T3 (da)
EA (1) EA014668B1 (da)
EE (1) EE05536B1 (da)
ES (1) ES2342024T3 (da)
GE (1) GEP20104915B (da)
HR (1) HRP20090524C1 (da)
LT (1) LT5589B (da)
LV (1) LV13630B (da)
ME (1) ME01192B (da)
PL (1) PL2013166T3 (da)
PT (1) PT2013166E (da)
SI (1) SI2013166T1 (da)
UA (1) UA96440C2 (da)
WO (1) WO2007104780A2 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LV14346B (lv) * 2009-11-05 2011-07-20 Grindeks, A/S 2-(4-Fenil-5-metil-2-oksopirolidin-1-il)-acetamīda 4R,5S-enantiomērs ar nootropo aktivitāti
RU2013141257A (ru) * 2011-03-11 2015-04-20 Гриндекс 4r, 5r-энантиомер 2-(5-метил-2-оксо-4-фенилпирролидин-1-ил) ацетамида с ноотропной активностью
RU2480214C1 (ru) 2011-09-22 2013-04-27 Валентина Ивановна Ахапкина Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов
DK3517541T3 (da) 2012-05-08 2020-09-07 Nicox Ophthalmics Inc Polymorf form af fluticasonpropionat
TW201408294A (zh) 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療帕金森氏症之用除
TW201408293A (zh) 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療疾病相關疲勞之用途
LV15003B (lv) * 2013-10-22 2015-08-20 Latvijas Organiskās Sintēzes Institūts Farmaceitiska kompozīcija ķermeņa masas pieauguma kontrolei
LV15015B (lv) 2013-12-13 2015-12-20 Olainfarm, A/S 3-karboksi-4-(R)-fenilpirolidin-2-ona sāls un tā pielietošana
LV15016B (lv) * 2013-12-18 2016-01-20 Olainfarm, A/S N-karbamoilmetil-4(R)-fenil-2-pirolidinona polimorfās formas
EP2891491A1 (en) 2014-01-03 2015-07-08 Merz Pharma GmbH & Co. KGaA Use of (r)-phenylpiracetam for the treatment of sleep disorders
LV15072B (lv) 2014-05-14 2016-09-20 Olainfarm, A/S Farmaceitiska kompozīcija izmantošanai patoloģiska stāvokļa, kam raksturīga paaugstināta iNOS gēna ekspresija, profilaksei un ārstēšanai
EP3127539A1 (en) * 2015-08-03 2017-02-08 Latvian Institute Of Organic Synthesis Use of 2-(5s-methyl-2-oxo-4r-phenyl-pyrrolidin-1-yl)-acetamide in the treatment of seizures
WO2024049236A1 (ko) * 2022-08-31 2024-03-07 고려대학교 산학협력단 키랄 감마 락탐 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 제조방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
RU2232578C1 (ru) * 2003-04-10 2004-07-20 Ахапкина Валентина Ивановна Вещество, обладающее антидепрессивной активностью
RU2289404C1 (ru) * 2005-04-06 2006-12-20 ГОУ ВПО "Московский государственный медико-стоматологический университет Министерства здравоохранения РФ" Способ премедикации у пациентов со средним уровнем психоэмоционального напряжения при амбулаторных стоматологических вмешательствах

Also Published As

Publication number Publication date
WO2007104780A2 (en) 2007-09-20
CA2647206A1 (en) 2007-09-20
US20100022784A1 (en) 2010-01-28
ES2342024T3 (es) 2010-06-30
ATE460396T1 (de) 2010-03-15
HRP20090524A2 (hr) 2009-12-31
ME01192B (me) 2012-12-20
DE602007005244D1 (de) 2010-04-22
GEP20104915B (en) 2010-03-10
PT2013166E (pt) 2010-06-09
LT5589B (lt) 2009-08-25
EA200801978A1 (ru) 2009-04-28
CA2647206C (en) 2011-09-27
LV13630B (en) 2007-12-20
CN101448786A (zh) 2009-06-03
WO2007104780A3 (en) 2007-11-29
PL2013166T3 (pl) 2010-08-31
EP2013166B1 (en) 2010-03-10
EE05536B1 (et) 2012-04-16
EP2013166A2 (en) 2009-01-14
US9382203B2 (en) 2016-07-05
CY1110170T1 (el) 2015-01-14
SI2013166T1 (sl) 2010-07-30
LT2008075A (en) 2009-06-25
UA96440C2 (ru) 2011-11-10
US20150216846A1 (en) 2015-08-06
EA014668B1 (ru) 2010-12-30
US9102615B2 (en) 2015-08-11
HRPK20090524B3 (hr) 2012-12-31
EE200800063A (et) 2008-12-15
HRP20090524C1 (hr) 2017-03-10

Similar Documents

Publication Publication Date Title
DK2013166T3 (da) N-carbamoylmethyl-4(R)-phenyl-2-pyrrolidon, fremgangsmåde til fremstilling heraf og farmaceutisk anvendelse
DK1687049T3 (da) Sprøjter, sprøjtegrænseflader og sprøjtestempler til anvendelse med medicinske injektorer
MY149705A (en) Pyridino-pyridinone derivatives, preparation therof, and therapeutic use thereof
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
IL180286A0 (en) Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
DE602007012473D1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
ZA200805385B (en) Novel, acyclic substituted furopyrimidine derivatives and use thereof for treating cardiovascular diseases
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
ATE528309T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
EA200701072A1 (ru) Препараты бензотиазола и их применение
EA200801211A1 (ru) Производные 9-хлор-15-простагландина, способ их получения и использования в лекарственных препаратах
WO2009024838A3 (en) Impression and model components
DE502007002949D1 (de) Proteinbindende methotrexat-derivate und diese enthaltende arzneimittel
CY1116166T1 (el) Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori
NO20091386L (no) Fenyloksyanilinderivater
EA200801977A1 (ru) Способ получения r-энантиомера n-карбамоилметил-4r-фенил-2-пирролидона
ATE481392T1 (de) Benzimidazolderivate zur behandlung entzündlicher erkrankungen
UA87524C2 (ru) Бензотиазолсодержащая композиция с макроголглицеридом и ее использование
UA99579C2 (ru) АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С Tau, ФОСФОРИЛИРОВАННЫМ ПО СЕРИНУ 422 (pS422), ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ ТАУПАТИИ
ATE502003T1 (de) L-(-)-moprolol-l-(+)-tartrat